SEC Form 4 · accession 0001171843-15-005929
Protara Therapeutics, Inc. · TARA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy P Noyes
Officer — President and CEO · Director
Period of report
Nov 2, 2015
Accepted (ET)
Nov 3, 2015 · 4:40 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001359931
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 2, 2015 | M | 5,000 | $1.91 | A | 5,000 | D | |
| Common StockF2 | Nov 2, 2015 | S | 5,000 | $13.50 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $1.91 | Nov 2, 2015 | M | 5,000 | D | — | Apr 19, 2016 | Common Stock, $0.001 par value | 5,000 | 68,742 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 25, 2015.
- F2All shares were sold at a price of $13.50 per share.
- F3The option was granted on April 19, 2006. All shares underlying the option have vested.